Magazines

Books, Abstracts and comunications about congresses

Magazines

• Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balana C, Martinez E, Herrero A, Pardo B, Adrover E, Rifa J, Godes MJ, Moyano A, Cervantes A. Ann Oncol 2005; 16: 749 – 755

• Ovarian cancer treatment: what is new. A. Poveda. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:241-50.

• Is combination chemotherapy superior to single-agent chemotherapy in second-line treatment? A. Gonzalez-Martin; Geico Group. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:185-91.

• Topotecan in platinum-resistant advanced ovarian cancer (AOC) patients (PTS): Evaluation of activity and prognostic factors of response: preliminary results. A study of Spanish Group for Research on Ovarian Cancer (GEICO). V.Soriano, C.Balañá, M.A.Izquierdo, A.Herrero, J.M. del Campo, A.Cervantes, A.Poveda, I.Bover, A.Casado, A.Arcusa, B.Ojeda, T.Massuti, I.Tusquets, I.Álvarez, E.Calvo. Ann Oncol.2000.vol II (suppl.4):85

• A combination of a fixed dose of Carboplatin plus paclitaxel and adiamycin in first-line therapy for advanced ovarian cancer and supoptimal surgical cytorreduction. A phase I trial of the Spanish Group for Ovarian Cancer Research and treatment (GEICO). A.Cervantes, A.Poveda, A.González, B.Massuti, C.Balañá, A.Insa. Eur.J.Cancer 1999; 35(Suppl 4): S239.

• Dose-Escalated Paclitaxel in 1-Hour Infusion with a Fixed Dose of Cisplatin in Previously Untreated Advanced Ovarian Cancer: A Phase II Trial of the Spanish Group for Ovarian Cancer. A.Cervantes, C.Mendiola, JM del Campo, B.Massuti, A.Casado, A.Escobedo, A.Moyano, B.Ojeda, A.Poveda and D.Benito. Seminars in Oncology 1997; vol 24, Nº 5 (Suppl 15) : S15-S43.

• A Phase II Trial of High Dose Single Agent Paclitaxel as First Line Therapy in Advanced Ovarian Cancer. A. Cervantes, A. Escobedo, JM del Campo, A. Poveda, MD Benito, JR Germá-Lluch. Annals of Oncology 1996; 7 (suppl 5): 76.

Abstracts

• Prolonged Infusion Of Gemcitabine In Patients With Platinum Resistant Or Refractory Recurrent Ovarian Carcinoma: A Phase II Study Of GEICO (Spanish Group For Investigation On Ovarian Cancer). B. Ojeda, A. Gonzaléz-Martín, B. Mellado, I. Bover, X. Fabregat, M. Rubio, L. Alonso, P. Lianes, C. Churruca, A. Poveda. 2005 ASCO Annual Meeting. Abstract No: 5101

• Early stages (I-IIa) epithelial ovarian cancer (EOC): preliminary data of the prospective register of the Spanish Group for Investigation on Ovarian Cancer (GEICO). B. Ojeda. 29th ESMO Congress 29 October – 2 November 2004 Vienna, Austria.

• First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival. G. B. Kristensen, I. Vergote, E. Eisenhauer, M. Baekelandt, G. Stuart, E. Aavall-Lundquist, J. Del Campo, A. B. Lopez, M. Mirza, E. Lorenz. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 5003

• Randomised phase II study of carboplatin (C) versus paclitaxel-carboplatin (PC) in platinum-sensitive (PS) recurrent advanced ovarian carcinoma (AOC) with assessment of quality of life (QoL): A GEICO study (Spanish Group for Investigation on Ovarian Carcinoma). A. Gonzalez Martin, E. Calvo, I. Bover, M. J. Rubio, A. Arcusa, A. Casado, B. Ojeda, C. Balana, M. C. Gonzalez, A. Herrero, Amadeo Pelegri, A Cervantes. Proc Am Soc Clin Oncol 22: page 451, 2003 ASCO Annual Meeting (abstr 1812).

• Predictors of response to pegylated liposomal doxorubicin in platinum pre-treated ovarian cancer (PPOC). A GEICO study (Spanish Group for Research And Treatment of Ovarian Cancer). Casado Herraez, A. Gonzalez, A. Cervantes, I. Bover, A. Poveda, I. Alvarez, A. Herrero, E. Calvo, A. Santaballa, B. Ojeda, for GEICO (Spanish Group on Research of Ovarian cancer). Proc Am Soc Clin Oncol 22: page 483; 2003 ASCO Annual Meeting (abstr 1942).

• “Registro prospectivo de estadíos I y II”. B. Ojeda, M J Godes, A. Herrero, A. Casado, A. Pelegri, I. Alvarez, A.Santaballa, A. Poveda, A. Carrato, A. González, C. Balaña, E. Martínez, A. Arcusa, A. Cervantes, I. Bover, X. Fabregat, E. Calvo y P. Lianes. Grupo GEIO. Libro de Abstracts de la SEOM (2003). Congreso de Tenerife.

• Predictors of response to pegylated liposomal doxorubicin (Caelix/Dexil) in platinum pre-treated ovarian cancer (PPOC): an interim análisis. A.Casado, A.Cervantes, I. Bover, B.Ojeda, I.Alvarez, A.Conzalez, IlTusquets. Proceedings ASCO, 2002; 21

• Doxorrubicina liposómica (Caelyx) en el tratamiento de enfermas con cáncer avanzado de ovario resistentes a platino: Evaluación de la actividad y de los factores pronóstico (FP) de respuesta (R). Resultados preliminares. Estudio del Grupo Español de Investigación en Cáncer de Ovario. A.Casado, A.Cervantes, I.Bover, B.Ojeda, I.Álvarez, A.Poveda, A.González, I.Tusquets, A.Antón, A.Santaballa. Libro Abstracts Congreso SEOM, 2001.

• Topotecan in platinum-resistant advanced ovarian cancer (aoc) patients (pts): evaluation of activity and prognostic factors of response: preliminary results. A study of the Spanish Group for Research on Ovarian Cancer (GEICO). V.Soriano, C Balaña, MA Izquierdo, A Herrero, JM del Campo, A Cervantes, A Poveda. I Bover, A Casado, A Arcusa, B Ojeda, T Massutti, I Tusquets, I Alvarez, E Calvo. 2000

• A phase I-II trial of a combination of a fixed dose of carboplatin with paclitaxel plus doxoribicin in first-line treatment for patients with advanced ovarian cancer with supoptimal cytoreduction. A GEICO Study. Proceedings of State of the Art in the Treatment of Ovarian Cancer. A.González, A.Cervantes, C.Balañá, T.García, B.Massuti and A.Poveda. El Escorial, 5th Nov 1999.

• Estudio en fase I de combinación de una dosis fija de carboplatino con paclitaxel y adriamicina en primera línea de tratamiento de pacientes con carcinoma de ovario avanzado y citorreducción inicial subóptima. Estudio del GEICO. A.Cervantes, A.Poveda, A.González, B.Massuti, C.Balañá, A.Insa. Libro Abstract C-178. Congreso SEOM, 1999.

• Phase II non-randomized trial of intrapatient escalating paclitaxel oves 1-hour infusion and fixed-dose cisplatin in advanced ovarian cancer. J.M.del Campo, C.Mendiola, B.Massuti, A.Casado, A.Cervantes, J.R.Germá, A.Moyano, B.Ojeda, A.Poveda, D.Benito. Proceedings ESGO, Lisboa 1997.

• Phase II study of paclitaxel in 1-hour infusion with dose escalation and fixed cisplatin in untreated advanced ovarian carcinoma. C. Mendiola, JM del Campo, B.Massuti, A. Casado, A.Cervantes, A. Escobedo, A. Moyano, B.Ojeda, A. Poveda, H.Gómez, FJ Vega and D. Benito. Proceedings ASCO 1997; 16: c-1276.